SNY vs. TECH: Sanofi vs. Bio-Techne Stock Comparison

Company Profile

Sanofi (SNY) and Bio-Techne (TECH) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but SNY is classified in Pharmaceuticals while TECH is classified in Life Sciences Tools & Services.

Bio-Techne (TECH) trades as ordinary local shares, while Sanofi (SNY) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Bio-Techne (TECH) at 8.33% sits in the top ROE quartile, while Sanofi (SNY) at 5.72% is closer to the peer norm — stronger capital efficiency for TECH.

For every dollar of sales, both Sanofi (SNY) at 8.20% and Bio-Techne (TECH) at 14.00% retain more as net profit than most peers, landing in the top net margin quartile of their industries.

Sanofi (SNY) at 30.89% operates in the top operating margin quartile, ahead of Bio-Techne (TECH) at 12.21%, which runs around its industry’s norm.

Profitability Metrics

Growth

Both Sanofi (SNY) at 5.49% and Bio-Techne (TECH) at -0.38% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Bio-Techne (TECH) at 152.17% sits in the top EPS growth quartile, while Sanofi (SNY) at 39.43% is closer to the peer norm — faster per-share earnings growth for TECH.

Growth Metrics

Financial Strength

Both Sanofi (SNY) at 1.12 and Bio-Techne (TECH) at 2.28 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.

Both Sanofi (SNY) at 0.27 and Bio-Techne (TECH) at 0.13 fund their balance sheets with roughly industry-typical debt-to-equity mixes.

Financial Strength Metrics

Dividends

Sanofi (SNY) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Bio-Techne (TECH) reports a yield of 0.44%, ranking against industry peers normally.

Sanofi (SNY) reports payout ratio above 100% at 119.86%, meaning dividends exceeded current-period earnings and sustainability needs extra context. Meanwhile Bio-Techne (TECH) reports 27.59%, ranking against industry peers normally.

Dividend Metrics

Valuation

Sanofi (SNY) at 23.40 is near its industry’s usual P/E ratio, while Bio-Techne (TECH) at 62.74 sits in the richer quartile — TECH needs stronger growth or earnings quality to justify the premium.

Sanofi (SNY) at 2.21 sits in the cheaper P/S ratio quartile while Bio-Techne (TECH) at 9.31 prices around its industry’s middle — SNY costs less per dollar of sales, though read it alongside growth and margins.

Sanofi (SNY) at 1.38 sits in the lower P/B ratio quartile against book while Bio-Techne (TECH) at 5.28 is valued near its industry’s middle — SNY is cheaper on assets, though weigh it against ROE and asset quality.

Valuation Metrics